The 2021 FSHD Society Young Investigator Award at the International Research Congress was awarded to Giorgio Tasca, MD PhD, a neurologist at the Fondazione Policlinico Universitario in Rome, Italy. Dr…. Read More »
Giorgio Tasca wins 2021 Young Investigator Award
ReDUX4 trial result exceeds expectations
By June Kinoshita, Director of Research and Patient Engagement “Positive benefit/risk supports losmapimod’s potential to be a transformative therapy for the treatment of FSHD”—Fulcrum Therapeutics Fulcrum Therapeutics announced today that… Read More »
FSHD University Webinar – Fulcrum Clinical Trial Results
Join us on June 24 at 4:00 pm US ET for this special webinar on the findings from Fulcrum Therapeutics’ ReDUX4 clinical trial. The Fulcrum team will be sharing the… Read More »
Dynamics of DUX4 downstream networks
by Lawrence J. Hayward, MD PhD, University of Massachusetts Medical School To develop robust therapies for FSHD, we need a better understanding of the sequence of events occurring at the… Read More »
FDA grants fast track designation to Losmapimod
From Global Newswire. Read full release. CAMBRIDGE, Mass., May 12, 2021 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically… Read More »